Information for patients
This clinical trial investigates two different approaches for the prevention of kidney stones: the study medication empagliflozin and personalised dietary recommendations.
Professional information for doctors and nursing staff
EMPASTONE is a randomised clinical trial that investigates the efficacy of empagliflozin and personalized dietary recommendations in preventing kidney stones in patients with recurrent calcium kidney stones.
Swissmedic approves trial
March 2, 2026
EMPASTONE uses a study drug that is not authorised for the prevention of kidney stones. Authorisation from the Swiss medicines…
Cantonal Ethics Committee Bern approves study
January 6, 2026
The Bern Ethics Committee reviewed the study and approved it in January 2026. This confirms that the study meets the…
SNSF announces funding for EMPASTONE
June 1, 2025
In June 2025, the Swiss Nationanal Science Foundation (SNSF) announced that it would fund the EMPASTONE study. The study is…